SUMMARY Sequential measurements of brain glucose metabolism were carried out in a patient with Wilson's disease, before and after successful treatment with D-penicillamine. They demonstrate an evolution of regional metabolism consistent with clinical improvement. The first study showed marked hypometabolism in the putamen on both sides. The second analysis showed bilateral improvement, with predominant residual deficits in the right putamen, while clinical symptoms of striatal dysfunction persisted on the left side. This observation suggests that positron emission tomography is able to follow the neurological evolution in cases of Wilson's disease. 
SUMMARY Sequential measurements of brain glucose metabolism were carried out in a patient with Wilson's disease, before and after successful treatment with D-penicillamine. They demonstrate an evolution of regional metabolism consistent with clinical improvement. The first study showed marked hypometabolism in the putamen on both sides. The second analysis showed bilateral improvement, with predominant residual deficits in the right putamen, while clinical symptoms of striatal dysfunction persisted on the left side. This observation suggests that positron emission tomography is able to follow the neurological evolution in cases of Wilson's disease. Wilson 's disease (WD), or hepatolenticular degeneration' is mainly characterised by copper deposits in liver, brain and cornea.2 Among the treatments proposed, the copper chelator D-penicillamine is generally favoured.3 4 Other molecules such as triethylene tetramine dihydrochloride5 6 collected at 1 cm intervals, starting from the level of the cerebellum. The overlap between adjacent sections ensured a complete sampling of the activity contained in basal nuclei. Glucose metabolic rates were calculated using the following set of rate constants: kl = 0 092; k2 = 0-140; k3 = 0 075; k4 = 0'0056; lumped constant = 0-420. Control studies were carried out in 10 normal, age-matched volunteers. Regions of interest were drawn on caudate nuclei and putamina by reference to neuroanatomical landmarks, particularly the thalamus which was prominent on PET images, and to CT scans. Absolute metabolic rates were considered abnormal when deviating by more than 20% from control values. Relative metabolic rates were expressed in percent of mean gray metabolism. They were considered abnormal when differing from corresponding values in control subjects by more than 2 standard deviations.
Results and discussion
Absolute and relative metabolic rates in the propositus and in control subjects are shown in tables 1 and 2. A perfect match in the head's position between the two studies could not be achieved. However, the data collection mode was such that the entire volume of basal nuclei was sampled in adjacent, slightly overlapping sections. Regions of interest were defined on the head of the caudate nuclei and on putamina in the images where these structures were best visible (that is, in the second study). They were transferred and matched on the corresponding image of the first analysis as shown in the fig. It is readily apparent that mean gray glucose metabolism was affected neither by the disease nor by the treatment. In the first study (fig De Voider, Sindic, Goffinet a), the putamen and, to a lesser extent, the caudate nuclei were the only regions with significant hypometabolism. After 17 months of treatment (fig b) , glucose utilisation remained normal in all brain regions which were normal in the first study. There was 10% improvement of both relative and absolute metabolic rates in the putamen on both sides, however with a slightly larger deficit on the right side. After treatment, the putaminal anomalies were borderline in terms of absolute metabolic rates, but still clearly significant in terms of relative rates. In the caudate nuclei, post-treatment metabolic values were within the normal range.
In the present patient, mean brain glucose metabolism was not affected by Wilson's disease. This is in contrast to the study of Hawkins et al3 who found diffuse glucose hypometabolism in four Wilson's disease patients. It should be pointed out, however, that these patients had a long history of disease and apparently severe neurological and hepatic changes.
Our measurements suggest that, with the exception of the putamen and caudate nuclei, brain glucose metabolism is not affected by Wilson's disease, at least during the first stages of the disease. In spite of its common pathological involvement, the cerebellum, in particular, did not show any significant anomaly in the present study. As might be predicted, Dpenicillamine treatment did not alter global brain metabolism and resulted in a remarkable but incomplete recovery of glucose utilisation in the striatum. The metabolic and clinical evolutions were correlated: the right putamen remained, after treatment, slightly more affected than its left counterpart. This is in 
